Drug intelligence / Profile preview

PP004

Development stage: Preclinical
Lead developer: Plano
Modality: Small Molecules
Administration: Inhalation

Overview

PP004 is a generic solution for inhalation being developed by Plano Pharmaceuticals for the treatment of respiratory diseases. Plano Pharmaceuticals focuses on the development of generic sterile injectables and inhalation products specifically designed to address drug shortages in the North American market. As of early 2024, the specific active pharmaceutical ingredient (API) and molecular target for PP004 have not been publicly disclosed, and the product is listed as being in the ongoing stage of development within the company's pipeline.

Beyond the preview

Go deeper on PP004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP004.

Explore the full profile